SUBSCRIBE
SUBSCRIBE

Alexion

NEWS
Deals
4 Possible Biotech Takeover Targets for 2018
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
December 12, 2017
 · 
3 min read
 · 
Mark Terry
Deals
Activist Investor Urges Alexion to Sell Itself or Else
Despite a purge of the leadership team at Alexion, a key investor believes the company needs to do more in order to address its damaged reputation and lift its stock price.
December 8, 2017
 · 
2 min read
 · 
Alex Keown
Business
San Diego’s Halozyme Lands Potential $680M R&D Deal With Alexion
Alexion will use Halozyme’s ENHANZE drug-delivery technology to develop subcutaneous formulations for that company’s portfolio of products.
December 7, 2017
 · 
2 min read
 · 
Alex Keown
FDA
Alexion Wins Expanded Approval for Blockbuster Drug Soliris
Alexion is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
October 23, 2017
 · 
3 min read
 · 
Alex Keown
Job Trends
As Alexion Moves To Boston, Yale Eyes HQ Space For New Biotech Startups
September 18, 2017
 · 
1 min read
Job Trends
Why Alexion’s HQ Move Could Be A Smoke Screen To Distract From Investigations, Financial Woes
September 15, 2017
 · 
1 min read
Alexion is Under Investigation by the HHS Office of Inspector General
Deals
Through M&A, These 2 Biotechs Could Help a Refreshed Alexion Build Its Pipeline
September 13, 2017
 · 
2 min read
Alexion is Under Investigation by the HHS Office of Inspector General
Business
Alexion Wants a Fresh Start, Slashes 20% of Jobs and Will Move HQ to Boston
September 12, 2017
 · 
3 min read
Alexion is Under Investigation by the HHS Office of Inspector General
Business
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
July 27, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Genetown
Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
May 13, 2019
 · 
1 min read
Drug Development
New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
May 3, 2019
 · 
21 min read
Genetown
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
April 26, 2019
 · 
23 min read
Business
Alexion Reports First Quarter 2019 Results
April 25, 2019
 · 
18 min read
Deals
Alexion to Report First Quarter Results on Thursday, April 25, 2019
April 12, 2019
 · 
1 min read
Business
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
March 20, 2019
 · 
7 min read
Business
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
March 20, 2019
 · 
9 min read
Drug Development
Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve
March 8, 2019
 · 
15 min read
Genetown
Alexion to Present at the Cowen 39th Annual Health Care Conference
March 5, 2019
 · 
1 min read
Genetown
Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
February 28, 2019
 · 
6 min read
Load More